Israeli Startup Remepy Raises $36 Million to Develop AI-Driven Hybrid Drugs

Remepy, an Israeli startup specializing in hybrid drugs, has secured $36 million in a Series A funding round led by O.G. Venture Partners and M Ventures, the strategic investment arm of Merck KGaA. The round also included participation from existing and new investors such as NFX, Vine Ventures, TechAviv, and others, bringing the company’s total funding to $62 million. Founded in 2022 by serial entrepreneur Dr. Michal Tsur, along with Or Shoval, Eran Item, and Prof. Amir Amedi, Remepy employs around 60 people at its offices in Ramat Gan.

Remepy operates in a novel pharmaceutical category that combines prescription drugs with AI-based therapeutic applications. These hybrid drugs integrate drug treatment with adaptive physical, cognitive, and behavioral interventions into a unified therapy, significantly improving patient outcomes and enabling broad multidisciplinary care through standard prescriptions. Recently, Remepy announced a strategic collaboration with Merck KGaA in Darmstadt, Germany, to develop hybrid drugs targeting rare tumors.

One of Remepy’s key programs, Hybridopa, targets Parkinson’s disease and has demonstrated strong Phase II clinical results, showing improvements in both motor and non-motor symptoms. The company plans to initiate a global Phase III trial in the fourth quarter of 2026. Ziv Kopf, managing partner at O.G. Venture Partners, highlighted Remepy’s innovative approach by combining biotechnology, artificial intelligence, and digital health to redefine drug development and patient usage.